Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Launched by GLAXO WELLCOME · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Topical antifungal therapy.
• Patient must have:
• • Newly diagnosed clinical and histological hairy leukoplakia.
• • Positive HIV antibody by licensed ELISA or Western blot.
• • Exclusion Criteria
• Co-existing Condition:
• • Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
• Concurrent Medication:
• Excluded within 2 weeks of study entry:
• • Systemic antifungal treatment.
• * Excluded within 6 weeks of study entry:
• • Immunomodulators.
• • Systemic antiviral treatment.
• • Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
• Prior Medication:
• Excluded within 2 weeks of study entry:
• • Systemic antifungal.
• * Excluded within 6 weeks of study entry:
• • Immunomodulators.
• • Systemic antiviral treatment.
• * Excluded within 8 weeks of study entry:
• • Zidovudine (AZT) or other antiretroviral therapy.